Exelixis

Yahoo Finance • 7 days ago

Here’s What Analysts Think About Arcus Biosciences (RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm b... Full story

Yahoo Finance • 15 days ago

Biogen Announces Board Chair Transition

CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s... Full story

Yahoo Finance • 15 days ago

MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA

Moderna MRNA shares plunged around 10% in after-hours trading following the announcement that the FDA’s Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the biologics license application (BL... Full story

Yahoo Finance • 16 days ago

Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch

Earnings Call Insights: Exelixis, Inc. (EXEL) Q4 2025 MANAGEMENT VIEW * CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all components of our business,” reaffirming a “singular focus to buil... Full story

Yahoo Finance • 16 days ago

Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In

Exelixis, Inc. (NASDAQ:EXEL) is one of the best healthcare stocks under $50 to invest in. On February 4, Barclays revised the price target on Exelixis, Inc. (NASDAQ:EXEL) to $44 from $41 and maintained an Equal Weight rating on the shares,... Full story

Yahoo Finance • 2 months ago

Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $218.7 million dollar inflow -- that... Full story

Yahoo Finance • 3 months ago

Strategic Pharma Collaborations Propel RCC Market Growth

Company Logo The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of target... Full story

Yahoo Finance • 3 months ago

Friday 11/28 Insider Buying Report: EXEL, ONMD

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is... Full story

Yahoo Finance • 3 months ago

LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American... Full story

Yahoo Finance • 3 months ago

Exploring 3 High Growth Tech Stocks In The US Market

The United States market has recently experienced mixed performances, with the Dow Jones Industrial Average declining for two consecutive days while technology shares have shown signs of rebounding. Amidst these fluctuations, investors are... Full story

Yahoo Finance • 4 months ago

Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners. The firm also raised its price target on the... Full story

Yahoo Finance • 4 months ago

Exploring 3 High Growth Tech Stocks in US Market

As the U.S. market grapples with a mix of earnings reports and renewed U.S.-China trade tensions, major stock indexes have been under pressure, with the tech-heavy Nasdaq and other indices closing lower. In this environment, identifying hi... Full story

Yahoo Finance • 4 months ago

Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Raymond James upgraded Capri Holdings(... Full story

Yahoo Finance • 4 months ago

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)... Full story

Yahoo Finance • 4 months ago

Validea John Neff Strategy Daily Upgrade Report - 10/21/2025

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth a... Full story

Yahoo Finance • 4 months ago

Notable Monday Option Activity: AMGN, ISRG, EXEL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Amgen Inc (Symbol: AMGN), where a total volume of 12,526 contracts has been traded thus far today, a contract volume whic... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Apple, Cleveland-Cliffs, Oracle, KLA, Tempus AI and more

Check out the companies making the biggest moves midday: Apple — The Tim Cook-led company climbed 4% after the iPhone 17 series outsold the iPhone 16 series in China and the U.S. in the first 10 days of availability, according to Counterpo... Full story

Yahoo Finance • 4 months ago

Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight

New York, USA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight The pancreatic endocrin... Full story

Yahoo Finance • 5 months ago

Goldman says these 20 overlooked stocks are poised to spike this coming earnings season

Goldman Sachs has homed in on a list of stocks to pay attention to this earnings season. The bank highlighted 20 stocks it believes could spike on Q3 results. "Buy calls to position for a volatile but positive earnings season," derivatives... Full story

Yahoo Finance • 5 months ago

Bilibili Reaches Analyst Target Price

In recent trading, shares of Bilibili Inc (Symbol: BILI) have crossed above the average analyst 12-month target price of $26.51, changing hands for $27.34/share. When a stock reaches the target an analyst has set, the analyst logically ha... Full story